MX2010006162A - Sal tosilato de una trans-n-isobutil-3-fluoro-3-[3-fluoro-4-(pirro lidin-1-il-metil)fenil]ciclobutanocarboxamida. - Google Patents

Sal tosilato de una trans-n-isobutil-3-fluoro-3-[3-fluoro-4-(pirro lidin-1-il-metil)fenil]ciclobutanocarboxamida.

Info

Publication number
MX2010006162A
MX2010006162A MX2010006162A MX2010006162A MX2010006162A MX 2010006162 A MX2010006162 A MX 2010006162A MX 2010006162 A MX2010006162 A MX 2010006162A MX 2010006162 A MX2010006162 A MX 2010006162A MX 2010006162 A MX2010006162 A MX 2010006162A
Authority
MX
Mexico
Prior art keywords
fluoro
disorders
anecarboxamide
cyclobut
pyrrolidin
Prior art date
Application number
MX2010006162A
Other languages
English (en)
Inventor
Travis T Wager
Todd William Butler
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2010006162A publication Critical patent/MX2010006162A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a la sal tosilato de trans-Nisobutil-3-fluoro-3-[3-fluoro-4-(pirrolidin-1-ilmetil)-fen il]-ciclobutanocarboxamida (1): (ver fórmula 1) a solvatos (por ejemplo, hidratos) de la misma, a polimorfos de la misma, a composiciones farmacéuticas de la misma y a un método para tratar depresión, trastornos del humor, esquizofrenia, trastornos de ansiedad, trastornos cognitivos, enfermedad de Alzheimer, trastorno por déficit de atención (TDA), trastorno por déficit de atención con hiperactividad (TDAH), trastornos psicóticos, trastornos del sueño, obesidad, mareo, epilepsia, mareo por movimiento, enfermedades respiratorias, alergia, respuestas de las vías respiratorias inducidas por alergia, rinitis alérgica, congestión nasal, congestión alérgica, congestión, hipotensión, enfermedad cardiovascular, enfermedades del tracto Gl, hiper e hipomotilidad y secreción ácida del tracto gastrointestinal que comprende administrar una cantidad terapéuticamente eficaz de la misma.
MX2010006162A 2007-12-07 2008-12-04 Sal tosilato de una trans-n-isobutil-3-fluoro-3-[3-fluoro-4-(pirro lidin-1-il-metil)fenil]ciclobutanocarboxamida. MX2010006162A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US569607P 2007-12-07 2007-12-07
PCT/IB2008/003392 WO2009071988A1 (en) 2007-12-07 2008-12-04 Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-flu0r0-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide

Publications (1)

Publication Number Publication Date
MX2010006162A true MX2010006162A (es) 2010-06-25

Family

ID=40380628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006162A MX2010006162A (es) 2007-12-07 2008-12-04 Sal tosilato de una trans-n-isobutil-3-fluoro-3-[3-fluoro-4-(pirro lidin-1-il-metil)fenil]ciclobutanocarboxamida.

Country Status (15)

Country Link
US (1) US8178574B2 (es)
EP (1) EP2231630B1 (es)
JP (1) JP4566259B2 (es)
KR (1) KR20100075679A (es)
CN (1) CN101939306A (es)
AR (1) AR069611A1 (es)
AU (1) AU2008332880C1 (es)
CA (1) CA2708043C (es)
IL (1) IL205963A0 (es)
MX (1) MX2010006162A (es)
NZ (1) NZ585671A (es)
RU (1) RU2451016C2 (es)
TW (1) TW200932213A (es)
WO (1) WO2009071988A1 (es)
ZA (1) ZA201004768B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4585610B2 (ja) 2007-01-22 2010-11-24 ファイザー・プロダクツ・インク 治療用化合物のトシル酸塩およびその医薬組成物
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
TWI574969B (zh) * 2015-01-30 2017-03-21 美國禮來大藥廠 甲苯磺酸鹽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ251047A (en) * 1992-04-10 1996-09-25 Pfizer Acylaminoindole derivatives and medicaments
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP4585610B2 (ja) * 2007-01-22 2010-11-24 ファイザー・プロダクツ・インク 治療用化合物のトシル酸塩およびその医薬組成物

Also Published As

Publication number Publication date
US20100256213A1 (en) 2010-10-07
AU2008332880C1 (en) 2012-07-19
IL205963A0 (en) 2010-11-30
NZ585671A (en) 2012-06-29
CN101939306A (zh) 2011-01-05
CA2708043C (en) 2012-11-13
AU2008332880B2 (en) 2012-01-19
RU2010122972A (ru) 2011-12-10
CA2708043A1 (en) 2009-06-11
EP2231630B1 (en) 2012-11-07
ZA201004768B (en) 2011-03-30
JP2009161517A (ja) 2009-07-23
JP4566259B2 (ja) 2010-10-20
EP2231630A1 (en) 2010-09-29
WO2009071988A1 (en) 2009-06-11
KR20100075679A (ko) 2010-07-02
RU2451016C2 (ru) 2012-05-20
TW200932213A (en) 2009-08-01
AU2008332880A1 (en) 2009-06-11
US8178574B2 (en) 2012-05-15
AR069611A1 (es) 2010-02-03

Similar Documents

Publication Publication Date Title
MX2009007782A (es) Sal de tosilato de un compuesto terapeutico y composiciones farmaceuiticas de la misma.
RS20080173A (en) Histamine-3 receptor antagonist
DE602006018301D1 (de) Histamin-3-rezeptorantagonisten
WO2007138431A3 (en) Azabicyclic ether histamine-3 antagonists
WO2007105053A3 (en) Tetralines antagonists of the h-3 receptor
WO2007088450A3 (en) Chromane antagonist of the h-3 receptor
WO2007063385A3 (en) Spirocyclic amine histamine-3 receptor antagonists
MX2012007409A (es) Derivados de benzamida sustituidos.
JP2009161554A5 (es)
BRPI0513444A (pt) antagonistas do receptor da histamina 3
DE502005010170D1 (de) Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
NZ617334A (en) Cyclopropyl amine derivatives
EA201100423A1 (ru) Новые бензамиды, их получение и их применение в качестве лекарственных средств
BRPI0507374A (pt) moduladores do receptor de histamina-3
EA201290519A1 (ru) Положительные аллостерические модуляторы рецептора хинолин амида m1
MX2010006162A (es) Sal tosilato de una trans-n-isobutil-3-fluoro-3-[3-fluoro-4-(pirro lidin-1-il-metil)fenil]ciclobutanocarboxamida.
MY140011A (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
MX2011011477A (es) Derivados de isoxazol-piridazina.
MX2007003587A (es) Antagonistas de los receptores de histamina-3.
MX2011011489A (es) Derivados de isoxazol-piridina.
MX2011011273A (es) Derivados de isoxazol-pirazol.
NZ598083A (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
MX2011008336A (es) Derivados de dihidroquinolinona.
WO2006024955A8 (en) Azabicyclic amine histamine-3 receptor antagonists
HRP20130917T1 (hr) 5-(2-{[6-(2,2-difluoro-2-feniletoksi)heksil]amino}-1-hidroksietil)-8-hidroksikinolin-2-(1h)-on za lijeäśenje pluä†ne funkcije

Legal Events

Date Code Title Description
FA Abandonment or withdrawal